Harpoon Therapeutics presents HPN217 Phase 1 data in RRMM

Harpoon Therapeutics “reported data from the Phase 1 study of HPN217 in patients with RRMM in an oral presentation at the 65th American Society of Hematology, or ASH, Annual Meeting and Exposition in San Diego. Harpoon also announced the selection of 12 mg as the HPN217 RP2D. During the trial, 97 patients with RRMM who had received at least three prior therapies were enrolled across 15 dose escalation cohorts and three expansion regimens. As of the data cut-off of October 17, 2023, the data demonstrated: Clinical activity across a wide dose range; The maximum tolerated dose was not reached at the target dose using a step up approach; Optimal activity and safety profile was seen at 12 mg, which was declared the RP2D; The Overall Response Rate across 12 mg cohorts was 63%. In addition, the depth of response was most significant at 12 mg, with 53% of patients having a Very Good Partial Response or better.”